Bisoprolol Fumarate is a selective beta-blocker API indicated for strokes, heart attacks and kidney problems. The consumption of Bisoprolol Fumarate is in constant growth year after year in kilogram consumption. Its worldwide market share in Europe is 70%.
It exhibits a higher degree of selectivity for β1 receptors compared to other selective β1 blocking drugs, including metoprolol, betaxolol, and atenolol. Additionally it is beneficial in the treatment of arterial hypertension and angina pectoris.
- European facility. Plant succesfully audited by European customers
- EU-GMP certificate. COA available (USP and EP)
- Competitive price. Samples available 36 months stability
- CEP for Bisoprolol Fumarate. Number: RO-CEP 2015-243-Rev 01
EXPERTS IN DEVELOPING HIGH QUALITY PHARMACEUTICAL PRODUCTS
For more information please contact:
PRODUCT MANAGER
ÁLVARO ALIQUE ([email protected])
